

Nikita V Lomakin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9614181/publications.pdf>

Version: 2024-02-01

9
papers

261
citations

1937457
4
h-index

1588896
8
g-index

10
all docs

10
docs citations

10
times ranked

604
citing authors

#	ARTICLE	IF	CITATIONS
1	AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 531-534.	2.9	202
2	The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. <i>Inflammation Research</i> , 2021, 70, 1233-1246.	1.6	35
3	Evgeny Chazov: first thrombolysis for ischaemic stroke. <i>European Heart Journal</i> , 2019, 40, 2281-2283.	1.0	0
4	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 210-215.	1.4	7
5	Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor. <i>European Cardiology Review</i> , 2019, 14, 175-178.	0.7	6
6	Potential benefits of prasugrel and ticagrelor in diabetics are not substantiated by the Food and Drug Administration adverse event repository. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 142-143.	1.4	1
7	Meta-analyses of incomplete trial datasets: unreliable and potentially misleading. <i>Heart</i> , 2018, 104, 630-631.	1.2	1
8	Impact of CYP2C19 Polymorphism on Antiplatelet Potency of Prasugrel 5 and 10 mg Daily Maintenance. <i>Cardiology</i> , 2018, 140, 155-162.	0.6	3
9	Historical overview of studies on inflammation in Russia. <i>Inflammation Research</i> , 2013, 62, 441-450.	1.6	2